Salix Pharmaceuticals (SLXP) 152.76 $SLXP
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Four Stock Spotlight Names Near Buy Points
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
Several Stock Spotlight stocks are near correct buy points and might prove profitable trades if the current uptrend can find more traction. The Stock Spotlight's computer-generated screen highlights stocks with strong earnings, strong sales growth...
Salix, Gilead Among 5 Top Medical Leaders To Watch
at Investor's Business Daily - Fri Sep 05, 4:06PM CDT
Top-performing medical stocks can be a panacea for a depressed portfolio. Today's Tech Leaders - Medical Screen features some heavy hitters in the pharmaceutical field. The maker of gastrointestinal disorder drugs such as Pepcid, Salix...
Off the Charts
at The Street - Fri Sep 05, 10:31AM CDT
9/04/14: YY Inc. (YY) broke out above our consolidation level, triggering our entry price. Look for follow-through tomorrow.
Salix Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.81%
Comtex SmarTrend(R) - Thu Sep 04, 4:26PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $153.79 to a high of $158.16. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $157.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.
45.1% Return Seen to Date on SmarTrend Salix Pharmaceuticals Call (SLXP)
Comtex SmarTrend(R) - Wed Sep 03, 10:56AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 45.12% as of today's recent price of $158.28.
Technical Updates, Upcoming Conferences, Drug Trials, and Acquisition Updates - Research Reports on SL Green, Allstate, HCA Holdings, Alexion and Salix
PR Newswire - Wed Sep 03, 8:15AM CDT
Today, Analysts Review released its research reports regarding SL Green Realty Corp. (NYSE: SLG), The Allstate Corporation (NYSE: ALL), HCA (NYSE: HCA), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6173-100free.
Salix Submits Response to XIFAXAN(R) 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea
Business Wire - Tue Sep 02, 6:19AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that on August 29, 2014, it submitted its response to the March 7, 2011, Food and Drug Administration (FDA) Complete Response Letter (CRL) regarding the Company's supplemental New Drug Application (sNDA) for XIFAXAN(R) 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix's response, the FDA will have six months to issue a response.
Uptrend Call Working As Salix Pharmaceuticals Stock Rises 44.2% (SLXP)
Comtex SmarTrend(R) - Wed Aug 27, 9:37AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 44.18% as of today's recent price of $157.25.
Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...
After Big Run, Does Chip Designer NXP Have More Left?
at Investor's Business Daily - Tue Aug 26, 4:27PM CDT
Stock Spotlight has been serving up plenty of strong performers in recent weeks -- not surprising, since the market is in a confirmed uptrend. If the stock market has shown us one thing in recent weeks, it's that breakouts from late-stage bases can...
Pharma Equities Technical Analysis -- Sanofi, AstraZeneca, Novartis, Salix Pharma, and AcelRx Pharma
PR Newswire - Tue Aug 26, 7:50AM CDT
On Monday, August 25, 2014, the NASDAQ Composite ended at 4,557.35, up 0.41%, the Dow Jones Industrial Average finished the day 0.44% higher at 17,076.87, and the S&P 500 closed at 1,997.92, up 0.48%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 732.60, up 0.72%, with the index gaining 7.53% in the previous three months. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free research on these five companies can be accessed at:
Termination of Waiting Period, Appointment, Extension Expiration Date, Technical Update, and Financial Results - Research Reports on Salix, Allergan, Valeant, HCA Holdings and Puma Biotechnology
PR Newswire - Fri Aug 22, 7:50AM CDT
Today, Analysts Review released its research reports regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Allergan, Inc. (NYSE: AGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), HCA Holdings Inc. (NYSE: HCA) and Puma Biotechnology Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5912-100free.
S&P 500 Marks New High As Indexes Hold Gains
at Investor's Business Daily - Thu Aug 21, 3:30PM CDT
Major averages closed modestly higher Thursday after existing-home sales, weekly jobless claims and Philly Fed factory data came in above expectations. The Dow industrials led with a 0.4% gain, while the S&P 500 added 0.3% to a new high. The Nasdaq...
SALIX PHARMACEUTICALS
at Investor's Business Daily - Wed Aug 20, 5:56PM CDT
SALIX PHARMACEUTICALS (SLXP) fell 2.2% after Bloomberg reported that Allergan (AGN) takeover talks -- an effort to fend off Valeant's (VRX) hostile bid for Allergan -- are dormant. Salix closed down 2.3% after spiking 15.5% on Tue. on WSJ's report of...
Salix Pharmaceuticals Jumps on Takeover Rumours by Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:45PM CDT
Salix Pharmaceuticals (SLXP) shares surged 15.5% after The Wall Street Journal claimed that Allergan (AGN) has approached Salix to acquire it.
Major Indexes Turn Mixed; Jazz Pharmaceuticals Turns Up
at Investor's Business Daily - Wed Aug 20, 12:11PM CDT
Stocks have turned mixed after lingering in mildly lower territory early on. Thanks to Home Depot (HD) and Boeing (BA), the Dow Jones industrial average rose 0.2%. The S&P 500 edged up 0.1% after falling 0.2%. Meanwhile, the Nasdaq was near the flat...
Salix announces termination of HSR Waiting Period for pending merger with Cosmo Pharmaceuticals SpA
M2 - Wed Aug 20, 10:36AM CDT
Pharmaceutical company Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Tuesday a notice of the early termination of the waiting period for US antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to its merger with Cosmo Pharmaceuticals SpA (SIX:COPN).
Salix Pharmaceuticals Has Returned 46.4% Since SmarTrend Recommendation (SLXP)
Comtex SmarTrend(R) - Wed Aug 20, 9:11AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 46.40% as of today's recent price of $159.68.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Four Stock Spotlight Names Near Buy Points
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
Several Stock Spotlight stocks are near correct buy points and might prove profitable trades if the current uptrend can find more traction. The Stock Spotlight's computer-generated screen highlights stocks with strong earnings, strong sales growth...
Salix, Gilead Among 5 Top Medical Leaders To Watch
at Investor's Business Daily - Fri Sep 05, 4:06PM CDT
Top-performing medical stocks can be a panacea for a depressed portfolio. Today's Tech Leaders - Medical Screen features some heavy hitters in the pharmaceutical field. The maker of gastrointestinal disorder drugs such as Pepcid, Salix...
Off the Charts
at The Street - Fri Sep 05, 10:31AM CDT
9/04/14: YY Inc. (YY) broke out above our consolidation level, triggering our entry price. Look for follow-through tomorrow.
Salix Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.81%
Comtex SmarTrend(R) - Thu Sep 04, 4:26PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $153.79 to a high of $158.16. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $157.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.
45.1% Return Seen to Date on SmarTrend Salix Pharmaceuticals Call (SLXP)
Comtex SmarTrend(R) - Wed Sep 03, 10:56AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 45.12% as of today's recent price of $158.28.
Technical Updates, Upcoming Conferences, Drug Trials, and Acquisition Updates - Research Reports on SL Green, Allstate, HCA Holdings, Alexion and Salix
PR Newswire - Wed Sep 03, 8:15AM CDT
Today, Analysts Review released its research reports regarding SL Green Realty Corp. (NYSE: SLG), The Allstate Corporation (NYSE: ALL), HCA (NYSE: HCA), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6173-100free.
Salix Submits Response to XIFAXAN(R) 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea
Business Wire - Tue Sep 02, 6:19AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that on August 29, 2014, it submitted its response to the March 7, 2011, Food and Drug Administration (FDA) Complete Response Letter (CRL) regarding the Company's supplemental New Drug Application (sNDA) for XIFAXAN(R) 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix's response, the FDA will have six months to issue a response.
Uptrend Call Working As Salix Pharmaceuticals Stock Rises 44.2% (SLXP)
Comtex SmarTrend(R) - Wed Aug 27, 9:37AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 44.18% as of today's recent price of $157.25.
Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...
After Big Run, Does Chip Designer NXP Have More Left?
at Investor's Business Daily - Tue Aug 26, 4:27PM CDT
Stock Spotlight has been serving up plenty of strong performers in recent weeks -- not surprising, since the market is in a confirmed uptrend. If the stock market has shown us one thing in recent weeks, it's that breakouts from late-stage bases can...
Pharma Equities Technical Analysis -- Sanofi, AstraZeneca, Novartis, Salix Pharma, and AcelRx Pharma
PR Newswire - Tue Aug 26, 7:50AM CDT
On Monday, August 25, 2014, the NASDAQ Composite ended at 4,557.35, up 0.41%, the Dow Jones Industrial Average finished the day 0.44% higher at 17,076.87, and the S&P 500 closed at 1,997.92, up 0.48%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 732.60, up 0.72%, with the index gaining 7.53% in the previous three months. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free research on these five companies can be accessed at:
Termination of Waiting Period, Appointment, Extension Expiration Date, Technical Update, and Financial Results - Research Reports on Salix, Allergan, Valeant, HCA Holdings and Puma Biotechnology
PR Newswire - Fri Aug 22, 7:50AM CDT
Today, Analysts Review released its research reports regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Allergan, Inc. (NYSE: AGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), HCA Holdings Inc. (NYSE: HCA) and Puma Biotechnology Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5912-100free.
S&P 500 Marks New High As Indexes Hold Gains
at Investor's Business Daily - Thu Aug 21, 3:30PM CDT
Major averages closed modestly higher Thursday after existing-home sales, weekly jobless claims and Philly Fed factory data came in above expectations. The Dow industrials led with a 0.4% gain, while the S&P 500 added 0.3% to a new high. The Nasdaq...
SALIX PHARMACEUTICALS
at Investor's Business Daily - Wed Aug 20, 5:56PM CDT
SALIX PHARMACEUTICALS (SLXP) fell 2.2% after Bloomberg reported that Allergan (AGN) takeover talks -- an effort to fend off Valeant's (VRX) hostile bid for Allergan -- are dormant. Salix closed down 2.3% after spiking 15.5% on Tue. on WSJ's report of...
Salix Pharmaceuticals Jumps on Takeover Rumours by Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:45PM CDT
Salix Pharmaceuticals (SLXP) shares surged 15.5% after The Wall Street Journal claimed that Allergan (AGN) has approached Salix to acquire it.
Major Indexes Turn Mixed; Jazz Pharmaceuticals Turns Up
at Investor's Business Daily - Wed Aug 20, 12:11PM CDT
Stocks have turned mixed after lingering in mildly lower territory early on. Thanks to Home Depot (HD) and Boeing (BA), the Dow Jones industrial average rose 0.2%. The S&P 500 edged up 0.1% after falling 0.2%. Meanwhile, the Nasdaq was near the flat...
Salix announces termination of HSR Waiting Period for pending merger with Cosmo Pharmaceuticals SpA
M2 - Wed Aug 20, 10:36AM CDT
Pharmaceutical company Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Tuesday a notice of the early termination of the waiting period for US antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to its merger with Cosmo Pharmaceuticals SpA (SIX:COPN).
Salix Pharmaceuticals Has Returned 46.4% Since SmarTrend Recommendation (SLXP)
Comtex SmarTrend(R) - Wed Aug 20, 9:11AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 46.40% as of today's recent price of $159.68.
